AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,522.00GBp
12 Sep 2014
Price Change (% chg)

-17.00p (-0.38%)
Prev Close
4,539.00p
Open
4,556.00p
Day's High
4,585.50p
Day's Low
4,472.50p
Volume
1,966,283
Avg. Vol
2,192,616
52-wk High
4,946.41p
52-wk Low
3,106.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.39
Market Cap (Mil.): £57,058.62
Shares Outstanding (Mil.): 1,262.72
Dividend: 53.10
Yield (%): 3.76

Financials

  AZN.L Industry Sector
P/E (TTM): 45.79 32.65 33.52
EPS (TTM): 0.99 -- --
ROI: 5.03 18.10 17.33
ROE: 8.94 18.80 18.19
Search Stocks

UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

AstraZeneca drug misses goal in severe COPD but improves lung function

LONDON - An experimental drug from AstraZeneca - part of a new wave of injectable respiratory drugs designed for people who do not respond adequately to traditional inhalers - has shown mixed results in chronic lung disease.

08 Sep 2014

AstraZeneca drug misses goal in severe COPD but improves lung function

LONDON, Sept 8 - An experimental drug from AstraZeneca - part of a new wave of injectable respiratory drugs designed for people who do not respond adequately to traditional inhalers - has shown mixed results in chronic lung disease.

08 Sep 2014

UK court backs Teva rival to AstraZeneca lung drug

TEL AVIV - Teva Pharmaceutical Industries said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug.

03 Sep 2014

UPDATE 1-UK court backs Teva rival to AstraZeneca lung drug

TEL AVIV, Sept 3 - Teva Pharmaceutical Industries said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug.

03 Sep 2014

UK court backs Teva rival to AstraZeneca lung drug

TEL AVIV, Sept 3 - Teva Pharmaceutical Industries said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug.

03 Sep 2014

Weaker healthcare stocks weigh on European equities

* Bid target AstraZeneca falls; CEO says "back to normal"

02 Sep 2014

Exclusive: 'Back to normal' for AstraZeneca CEO, despite Pfizer rumors

BARCELONA - Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.

02 Sep 2014

Astra heart pill safe to use in ambulance but no extra benefit

BARCELONA, Sept 1 - AstraZeneca's blood-thinning drug Brilinta is safe to use in the ambulance when heart attack patients are being rushed to hospital but giving it early in this way does not provide any extra benefit.

01 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks